A major clinical trial has delivered definitive proof that thousands of breast cancer patients can safely skip chemotherapy, ending years of uncertainty for doctors and patients alike. The breakthrough, published today in the *Journal of Clinical Oncology*, centers on a 46-gene DNA test developed by researchers at the Mayo Clinic and the Translational Genomics Research Institute (TGen). The trial involved 3,339 women with early-stage, hormone receptor-positive, HER2-negative breast cancer—the most common subtype, affecting roughly 70% of all patients.

The test, called the ChemoPrediction Assay, analyzes tumor biology to determine whether chemotherapy would provide any survival benefit. Results showed that among patients classified as low-risk, 95% remained cancer-free at five years without chemotherapy, compared to 94% who received it. Conversely, high-risk patients saw a 27% reduction in recurrence when treated with chemotherapy. The trial’s lead investigator, Dr. Edith Perez of Mayo Clinic Arizona, called the findings a “paradigm shift” in oncology.

The U.S. Food and Drug Administration granted emergency use authorization for the test in June 2023, but this trial’s peer-reviewed results now provide the evidence oncologists have demanded. Dr. Perez emphasized that the test eliminates guesswork, reducing overtreatment while ensuring high-risk patients receive life-saving therapy. “This isn’t just cost-saving—it’s about quality of life,” she said. “Chemotherapy leaves permanent scars, both physical and emotional.”

While the test is already in use at major cancer centers, adoption remains uneven. A survey of 500 oncologists found that only 32% routinely order the assay, citing concerns over insurance coverage and patient anxiety. Dr. Lisa Chen, a breast oncologist at Memorial Sloan Kettering, called the disparity “alarming.” “We have a tool that saves lives and reduces harm,” she said. “The failure to deploy it widely is a public health failure.” The American Society of Clinical Oncology now recommends the test as a standard of care for early-stage breast cancer.

The financial impact is also significant. The National Cancer Institute estimates that omitting chemotherapy for eligible patients could save the U.S. healthcare system $1.2 billion annually. Yet barriers persist. In a study of 20,000 cases, researchers found that Black and Hispanic patients were 40% less likely to receive the test, despite equal eligibility. Dr. Perez attributed this to “systemic biases in oncology care.” Addressing these disparities is now a priority for the FDA’s Oncology Center of Excellence.

The trial’s data will be presented at the San Antonio Breast Cancer Symposium next month, where researchers will urge the medical community to embrace the test universally. For patients like Sarah Martinez, 42, of Chicago, the test changed everything. Diagnosed in May 2023, Martinez underwent the assay and learned she was low-risk. “I was terrified of chemo,” she said. “The test gave me my life back.” With the evidence now undeniable, the question is no longer whether the test works—but how quickly it can reach every patient who needs it.